Abstract
Both benign hyperplasia of prostate and hypertension show a high activity on alfa-1 adrenergic receptors (alfa-1 AR) that lead to high peripheral vasoconstriction (in hypertonic patients) and high stimulation of alfa-1 AR in the area of the neck of the urinary bladder, prostate and urethra (in BHP). The etiology of both BHP and essential HTN is unknown, and we cannot treat the cause of both the diseases.
Many men live with decompensated BHP and untreated HTN (assumptions are about 20%), a high percentage of men undergo BHP and HTN therapy that does not correspond to the latest knowledge of science (e.g. the minimum of 35% hypertonic patents from 58 ill people in the USA are insufficiently followed and treated). Pharmacologists differ on whether it is suitable to treat both the diseases by one medicine, if this medicine is not the medicine of first or second choice in at least one of these diseases.